Another historic day! Proud to announce a 5th #COVID19 vaccine candidate funded by #NIH & @BARDA began enrollment for its Phase 3 clinical trial. NVX-CoV2373, developed by @Novavax, will enroll up to 30k volunteers from U.S./Mexico. https://t.co/K9w2dxFmww
— Francis S. Collins (@NIHDirector) December 28, 2020
News: Phase 3 trial of Novavax investigational COVID-19 vaccine opens https://t.co/ApJW4gcfeF
— NIH (@NIH) December 28, 2020
The @Novavax #COVID19 vaccine candidate, NVX-CoV2373, uses a stabilized form of the coronavirus spike protein which cannot replicate to induce an immune response. It's administered in liquid form and can be stored/handled/distributed at a 35-46°F. https://t.co/ftL3gNxXzG pic.twitter.com/2ixvm0Z74j
— NIH (@NIH) December 28, 2020
Read more from @NIH ⬇️ https://t.co/wjlA4DQfZv
— Secretary Alex Azar (@SecAzar) December 28, 2020
.@Novavax launched a Phase 3 #clinicaltrial for #COVID19 vaccine candidate NVX-CoV2373 funded by @NIH & @BARDA. The investigational vaccine uses a stabilized form of the coronavirus spike protein (which cannot replicate) to induce an immune response. https://t.co/X3s0rx8C5a pic.twitter.com/gqWwQcWHhO
— HHS.gov (@HHSGov) December 28, 2020
The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at 115 sites in the United States and Mexico. https://t.co/OdDg2sWSRw
— C. Michael Gibson MD (@CMichaelGibson) December 28, 2020
We have another Phase III coronavirus vaccine trial here in the US, this one for Novavax’s vaccine candidate.
— Alicia Smith (@Alicia_Smith19) December 29, 2020
The trial is looking to recruit 30,000 people in the US. If you’re interested, click the link at the bottom of this article :) https://t.co/xT8QWYqEkm